<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366097">
  <stage>Registered</stage>
  <submitdate>1/04/2014</submitdate>
  <approvaldate>7/04/2014</approvaldate>
  <actrnumber>ACTRN12614000364673</actrnumber>
  <trial_identification>
    <studytitle>The effect of zopiclone on the respiratory arousal threshold in obstructive sleep apnoea</studytitle>
    <scientifictitle>The effect of zopiclone on the respiratory arousal threshold in obstructive sleep apnoea</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sleep apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zopiclone (7.5mg), once only immediately before going to bed, taken orally.

1 week washout</interventions>
    <comparator>Placebo (sugar pill), taken orally (participants will act as their own controls in a cross-over design)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Respiratory arousal threshold (negative pharyngeal pressure immediately prior to arousal from sleep using an epiglottic pressure catheter inserted via the nostril)</outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Genioglossus muscle activity during sleep measured using fine-wire intramuscular electromyography</outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Polysomnographic measures of sleep apnoea severity (e.g. AHI, sleep efficiency, arousal index, event duration, and nadir SaO2)</outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men and women with obtructive sleep apnoea</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-Known allergy or previous adverse reaction to zopiclone
-Pregnant or nursing mothers
-Patients with any other medical condition which may interfere in the evaluation of the study
- Patients taking medications known to affect sleep or muscle activity</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>It is estimated that studying 12 participants will allow us to detect a 4cmH2O difference (SD=4.5) in the respiratory arousal threshold between placebo and zopiclone conditions (paired t-test) with &gt;80% power. This calculation is based on a similar effect size for other common sedatives and a between night difference in the SD of the respiratory arousal threshold using similar methodology (e.g. Eckert el al, Clin Sci, 2011 and Eckert et al, Sleep 2014). </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>9/04/2014</anticipatedstartdate>
    <actualstartdate>15/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>29/10/2014</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Neuroscience Research Australia</primarysponsorname>
    <primarysponsoraddress>Barker Street
Randwick
NSW 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of New South Wales</fundingname>
      <fundingaddress>UNSW Medicine
University of New South Wales
SYDNEY NSW 2052</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC (APP1042493)</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this physiology study is to determine the effects of zopiclone (sedative) on the awakening (arousal) response to respiratory stimuli during sleep and on upper airway muscle activity and breathing during sleep.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>Nil</publicnotes>
    <ethicscommitee>
      <ethicname>University of New South Wales Human Research Ethics Committee</ethicname>
      <ethicaddress>UNSW Grants Management Office
Rupert Myers Building, Level 3, South Wing
The University of New South Wales 
SYDNEY NSW 2052</ethicaddress>
      <ethicapprovaldate>13/03/2012</ethicapprovaldate>
      <hrec>HC12028</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>